93. An immunogenic composition according to any one of the preceding claims wherein the polypeptide elicits a protective immune response in a mammalian host against strains of *C.difficile*.

94. The immunogenic composition of any one of the preceding claims wherein the polypeptide comprises less than 25%, 20%, 18% or 15% alpha helical structure.

95. The immunogenic composition of any one of the preceding claims wherein the polypeptide comprises more than 25%, 30%, 35%, 38% or 40% beta sheet structure.

96. The immunogenic composition of any one of the preceding claims further comprising additional antigens.

97. The immunogenic composition of claim 96 wherein the additional antigens are antigens derived from a bacterium selected from the group consisting of *Streptococcus pneumonia, Haemophilus influenzae*, *Neisseria meningitidis*, *Escherichia coli*, *Moraxella catarrhalis*, *Clostridium tetani, Corynebacterium diptherieriae, Bordetella pertussis, Staphylococcus epidermidis*, enterococci, and *Staphylococcus aureus* .

98. The immunogenic composition of any one of the preceding claims further comprising a saccharide from *C.difficile*.

99. A vaccine comprising the immunogenic composition of any one of the preceding claims and a pharmaceutically acceptable excipient.

~~100. A use of the immunogenic composition of any one of the preceding claims or the vaccine of claim 99 in the treatment or prevention of *C.difficile* disease.~~

~~101.~~100. The immunogenic composition of any one of the preceding claims or the vaccine of claim 99 for use in the treatment or prevention of *C.difficile* disease.

~~102.~~101. A use of the immunogenic composition of any one of the preceding claims or the vaccine of claim 99 in the preparation of a medicament for the prevention or treatment of *C.difficile* disease.

~~103. A method of preventing or treating *C.difficile* disease comprising administering the immunogenic composition of any one of the preceding claims or the vaccine of claim 99 to a mammalian subject.~~